Yuflyma was the world’s first proposed high-concentration, low-volume and citrate-free adalimumab biosimilar to receive European Commission approval in Europe. FDA for Yuflyma, tentatively expected Q4 in 2024.Ībout Yuflyma ® (CT-P17, biosimilar adalimumab-aaty) 1 Visit to learn more.Ĭelltrion is seeking an interchangeability designation from the U.S. Nurses will be available to answer patient questions and provide training. Patients who are uninsured or underinsured may be eligible to receive Yuflyma through the Celltrion CONNECT ® Patient Assistance Program (PAP). Eligible patients with private/commercial insurance may receive Yuflyma for as little as $0 out of pocket per month. The Patient Support Program for Yuflyma will provide benefits verification, prior authorization assistance, and co-pay assistance. To improve patients’ and healthcare providers’ experience using Yuflyma, Celltrion USA is proud to offer Celltrion CONNECT ® Patient Support Program along with Celltrion CARES™ Co-pay Assistance Program beginning July 10 th. This formulation can reduce injection discomfort for patients with chronic conditions like rheumatoid arthritis, thereby improving adherence to treatment.” Professor Jonathan Kay of UMass Chan Medical School, said: “The launch of Yuflyma provides patients with one of only a few FDA-approved adalimumab biosimilars that has a high-concentration, citrate-free formulation. Celltrion has a demonstrated track record of commercial, regulatory and manufacturing success globally – including the first monoclonal antibody biosimilar infliximab– and our dedicated immunology commercial team is ready to leverage their experience and market knowledge in the U.S.” “We are committed to providing a patient-centric approach with a focus on increased access to innovative, high-quality biologics in the United States. “The launch of Yuflyma is a critical milestone not only for Celltrion USA, but for patients, healthcare providers, and payers,” said Tom Nusbickel, Chief Commercial Officer at Celltrion USA. It also maintains stability at 25℃ (77☏) for 30 days to provide longer shelf life than Humira and is administered via a latex-free device. 2 Yuflyma is a citrate-free formulation that is highly concentrated at 100mg/mL. rely on a high-concentration and citrate-free formulation. More than 80% of patients treated with Humira in the U.S. Yuflyma is available in two device types - auto-injector and pre-filled syringe options. Yuflyma is listed at $6,576.50 per month. 1įirst approved by the Food and Drug Administration on May 23, 2023, Yuflyma became commercially available among key distributors across the U.S. Yuflyma is indicated for the treatment of eight conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa. JERSEY CITY, N.J.-( BUSINESS WIRE)-Celltrion USA today announced the launch of Yuflyma ® (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira ® (adalimumab) biosimilar, providing an alternative option for patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |